While FDA regulatory actions capture headlines, the agency’s efforts to advance medical product development and manufacturing usually get little attention. That information is now available in a report listing the agency’s recent regulatory science accomplishments, which range from qualifying three new biomarkers for use in clinical trials to developing tools for studying continuous manufacturing.
FDA posted the document, “FY 2015-2016: Regulatory Science Progress Report,” on its website March 29. This is the agency's second progress report, which it is required to publish...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?